 WESTLAKE VILLAGE, Calif., Nov. 02, 2020 GLOBE NEWSWIRE -- Arcutis Biotherapeutics, Inc. Nasdaq: ARQT, a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today reported new positive data from previously announced Phase 2 studies of ARQ-151 topical roflumilast cream in patients with chronic plaque psoriasis and atopic dermatitis. The data is being presented at the European Academy of Dermatology and Venereology EADV Virtual Congress EADV Virtual, Society of Dermatology Physician Assistants SPDA Digital 2020 conference, and virtual 2020 Fall Clinical Dermatology Conference. 